Developing technologies in biodefense research: Computational drug design

Matthew Clark, Sia Meshkat, George Talbot, Zenon Konteatis, Jennifer Ludington, Jinming Zou, Steven J. Freedman, Jeffrey S. Wiseman

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


The development of small-molecule drugs to counter the threat of bioterrorism will differ from classical drug discovery because it will be impossible to evaluate efficacy in clinical trials for many agents. This difference focuses biodefense on the identification of multiple drug candidates for each threat organism so that multiple treatments can be mounted simultaneously when needed to maximize the probability of success. Accordingly, drug discovery will become the rate- and cost-limiting phase of the overall drug development process. We address the potential of computational chemistry to optimize efficiency and efficacy in the discovery phase. The major elements required for a successful computational approach are the calculation of binding free energy, accounting for changes in solvation on ligand binding, and compensating for protein flexibility.

Original languageEnglish
Pages (from-to)279-287
Number of pages9
JournalDrug Development Research
Issue number4
StatePublished - Jun 1 2009
Externally publishedYes


  • Computation
  • Drug-design
  • Free-energy


Dive into the research topics of 'Developing technologies in biodefense research: Computational drug design'. Together they form a unique fingerprint.

Cite this